4 min listen
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
FromASCO Education
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
FromASCO Education
ratings:
Length:
11 minutes
Released:
Jun 27, 2018
Format:
Podcast episode
Description
Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.
Released:
Jun 27, 2018
Format:
Podcast episode
Titles in the series (100)
Self-Evaluation: Metastatic Breast Cancer: Self-Evaluation: Metastatic Breast Cancer by ASCO Education